ライフサイエンスコーパス: adverse drug event

1 ial resistance can often be thought of as an adverse drug event.

2 trum antibiotic use, treatment failures, and adverse drug events.

3 ared with 177 (18.7%) of the 945 significant adverse drug events.

4 ation categories associated with preventable adverse drug events.

5 D visits and subsequent hospitalizations for adverse drug events.

6 is very expensive and often associated with adverse drug events.

7 ug interactions (DDIs) are a common cause of adverse drug events.

8 7 cases, there was a total of 499 documented adverse drug events.

9 ied those that could be harmful as potential adverse drug events.

10 for our patients and, in particular, reduce adverse drug events.

11 mps to critically ill patients can result in adverse drug events.

12 rs included both near-misses and preventable adverse drug events.

13 ncidence and nature of medication errors and adverse drug events.

14 in 1.8% (95% CI, 1.5%-2.1%) of ED visits for adverse drug events.

15 ts were the most common types of preventable adverse drug events.

16 survey (response rate, 55 percent), 162 had adverse drug events (25 percent; 95 percent confidence i

17 59.9% (95% CI, 56.8%-62.9%) of ED visits for adverse drug events; 4 anticoagulants (warfarin, rivarox

18 ic treatment, 75 and 42), had frequent minor adverse drug events (53% and 55%), reported significant

19 Of the adverse drug events, 578 (38.0%) were categorized as ser

20 Adverse drug events accounted for 2.5% (95% CI, 2.0%-3.1

21 atements pertaining to medication errors and adverse drug events addressing the key components.

22 Adverse drug events (ADEs) are a significant and costly

23 Adverse drug events (ADEs) are the most common type of i

24 Adverse drug events (ADEs) constitute one of the leading

25 ill patients are particularly susceptible to adverse drug events (ADEs) due to their rapidly changing

26 They include preventable or ameliorable adverse drug events (ADEs), as well as medication discre

27 ence has shown that sex differences exist in Adverse Drug Events (ADEs).

28 Adverse drugs events (ADEs) detection constitutes a cons

29 dication administration as well as potential adverse drug events, although it did not eliminate such

30 Adverse drug events among outpatients that lead to emerg

31 However, few data are available on adverse drug events among outpatients.

32 .0% (95% CI, 0.6%-1.4%) of ED visits for all adverse drug events among patients>/=40 years, but an es

33 % CI, 4.0%-7.9%) of hospitalizations for all adverse drug events among patients>/=85 years.

34 hose individuals involved in the preventable adverse drug event and potential adverse drug event unde

35 tion errors, including 14 and 11 preventable adverse drug events and 73 and 82 nonintercepted potenti

36 represented adverse drug events or potential adverse drug events and as to severity and preventabilit

37 ss, they tend to overlook the possibility of adverse drug events and medication errors in their diffe

38 The rate of preventable adverse drug events and potential adverse drug events in

39 Preventable adverse drug events and potential adverse drug events oc

40 re was no greater likelihood for preventable adverse drug events and potential adverse drug events to

41 Rate of preventable adverse drug events and potential adverse drug events, l

42 eal-time or near real-time identification of adverse drug events and potentially afford the practitio

43 ctor for prescribing and adherence problems, adverse drug events, and other adverse health outcomes.

44 rough optimization of drug use, avoidance of adverse drug events, and transitional care activities fo

45 e likely than younger individuals to sustain adverse drug events (annual estimate, 4.9 vs 2.0 per 100

46 elderly persons with age-related conditions, adverse drug events are an important cause of illness an

47 Adverse drug events are common and often preventable amo

48 Adverse drug events are common and often preventable cau

49 Adverse drug events are common in the intensive care uni

50 Adverse drug events are important preventable causes of

51 More serious adverse drug events are more likely to be preventable.

52 nd rationale for meaningful documentation of adverse drug events are provided, along with an outline

53 y 27.3% (P<0.001), but the rate of potential adverse drug events associated with timing errors did no

54 rated importance of pain relief relative to adverse drug event avoidance), preferred treatment thres

55 re unit teams, and patients involved in each adverse drug event by comparing ICUs with non-ICUs and m

56 The costs of an adverse drug event can be substantial to healthcare syst

57 d, nationally representative data describing adverse drug events can help focus these efforts.

58 The clinical outcomes of adverse drug events can result in end-organ damage and e

59 Over the 2-year study period, 21,298 adverse drug event cases were reported, producing weight

60 Adverse drug events cause substantial morbidity and mort

61 o polypharmacy could lead to improvements in adverse drug events, cost, and possibly quality of life.

62 l different methods are available for robust adverse drug event data collection, such as target chart

63 Aggregation of adverse drug event data has evolved in the last decade.

64 Antibiotic-associated adverse drug events decreased by 30%.

65 Continued development of adverse drug event detection will allow for further qual

66 t onset of drug-induced injury, known as an "adverse drug event." Drug-induced episodes were evaluate

67 No patients had serious adverse drug events during treatment and no patients sto

68 Disorders of coagulation are common adverse drug events encountered in critically ill patien

69 Adverse drug events, especially those that may be preven

70 31.8%; 95% CI, 28.7%-34.9%) in ED visits for adverse drug events, followed by antipsychotics (4.5%; 9

71 edications had a 3% higher risk of having an adverse drug event for each drug dispensed.

72 Critically ill patients are at high risk for adverse drug events for many reasons, including the comp

73 2005-2006, the proportions of ED visits for adverse drug events from anticoagulants and diabetes age

74 Although adverse drug events have been extensively evaluated by c

75 esults may facilitate the early diagnosis of adverse drug events in clinical application.

76 inal study was to determine risk factors for adverse drug events in critically ill adult patients.

77 An evaluation of risk factors for adverse drug events in critically ill patients has not b

78 ported with many drugs, and these are common adverse drug events in critically ill patients that can

79 ed characteristics contribute to the risk of adverse drug events in critically ill patients.

80 ant factor that contributes significantly to adverse drug events in current healthcare practice.

81 reventable adverse drug events and potential adverse drug events in ICUs was 19 events per 1000 patie

82 rdable Care Act of 2010 brought attention to adverse drug events in national patient safety efforts.

83 zation after emergency department visits for adverse drug events in older adults and to assess the co

84 st emergency hospitalizations for recognized adverse drug events in older adults resulted from a few

85 the potential to reduce hospitalizations for adverse drug events in older adults.

86 vents and 73 and 82 nonintercepted potential adverse drug events in the control and intervention peri

87 tics of emergency department (ED) visits for adverse drug events in the United States in 2013-2014 an

88 revalence of emergency department visits for adverse drug events in the United States was estimated t

89 idence interval [CI], 55,531 to 143,724) for adverse drug events in U.S. adults 65 years of age or ol

90 nd risks for emergency department visits for adverse drug events involving Beers criteria medications

91 lly representative information on outpatient adverse drug events is limited.

92 reventable adverse drug events and potential adverse drug events, length of stay, charges, costs, and

93 uch as adverse event, adverse drug reaction, adverse drug event, medication error, and side effect.

94 les from infectious disease surveillance and adverse drug event monitoring demonstrate that the techn

95 34.5% (95% CI, 30.3%-38.8%) of ED visits for adverse drug events occurred among adults aged 65 years

96 sits (95% CI, 100,155 to 254,854 visits) for adverse drug events occurred both years.

97 Adverse drug events occurred in 258 patients (30.3%) and

98 reventable adverse drug events and potential adverse drug events occurred in units that functioned no

99 Errors associated with preventable adverse drug events occurred most often at the stages of

100 stimated 4.0 (95% CI, 3.1-5.0) ED visits for adverse drug events occurred per 1000 individuals annual

101 There were 1523 identified adverse drug events, of which 27.6% (421) were considere

102 ent reviewers as to whether they represented adverse drug events or potential adverse drug events and

103 The rate of potential adverse drug events (other than those associated with ti

104 Clinical outcomes included rates of adverse drug events, patterns of antimicrobial resistanc

105 erson-years, with a rate of 13.8 preventable adverse drug events per 1000 person-years.

106 The objective of this article is to describe adverse drug events related to the liver and gastrointes

107 critically ill patients are associated with adverse drug events related to the liver and gastrointes

108 aper will review the most common and serious adverse drug events reported to occur with the use of se

109 3-times, and 2-times more likely to have an adverse drug event, respectively.

110 27.3% (95% CI, 22.2%-32.4%) of ED visits for adverse drug events resulted in hospitalization.

111 Number of adverse drug events, severity of the events (classified

112 th prescribing errors, risk to patients from adverse drug events should be reduced.

113 3-2014 and describe changes in ED visits for adverse drug events since 2005-2006.

114 ronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project (2007 through 20

115 ronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project and the National

116 ronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project.

117 ronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project.

118 i.e., scenarios presenting variable pain and adverse drug event symptoms in a child).

119 ts would withhold the prescribed opioid when adverse drug event symptoms were present together with h

120 The critically ill are more susceptible to adverse drug events than nonintensive care unit patients

121 However, nationally representative data on adverse drug events that result in hospitalization in th

122 es the case study of a patient with multiple adverse drug events to clarify key terms, such as advers

123 reventable adverse drug events and potential adverse drug events to occur in ICUs than in non-ICUs.

124 n level at which they would give an opioid), adverse drug event understanding, and hypothetical trade

125 preventable adverse drug event and potential adverse drug event underwent detailed interviews by peer

126 The overall rate of adverse drug events was 50.1 per 1000 person-years, with

127 The rate of preventable and potential adverse drug events was twice as high in ICUs compared w

128 acuity, length of stay, and severity of the adverse drug event were greater in ICUs than non-ICUs, b

129 Intravenous medication errors and adverse drug events were frequent and could be detected

130 dication classes most frequently involved in adverse drug events were selective serotonin-reuptake in

131 46.9% (95% CI, 44.2%-49.7%) of ED visits for adverse drug events, which included clinically significa